|
| Press Releases |
|
 |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
| Monday, January 18, 2021 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
| Monday, November 23, 2020 |
|
|
SinoMab Commenced Construction of its China Headquarters |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, July 23, 2020 |
|
|
SinoMab entered into Strategic Collaboration with D2M |
| SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, June 10, 2020 |
|
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Wednesday, October 30, 2019 |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
NEC and Siemens collaborate to accelerate smart factory innovation
Nov 4, 2025 0:57 JST
|
|
|
Exhibiting at the Space Tech Expo Europe 2025 in Bremen, Germany
Nov 4, 2025 0:49 JST
|
|
|
Honda Announces Electric Motorcycle Business Brand Promise and Four Core Values
Nov 4, 2025 0:35 JST
|
|
|
Honda Unveils Its First Electric Motorcycle, the Honda WN7, at EICMA 2025
Nov 4, 2025 0:20 JST
|
|
|
Honda Unveils V3R 900 E-Compressor Prototype Equipped with V3 Engine with Electronically-controlled Compressor at EICMA 2025
Nov 4, 2025 0:00 JST
|
|
|
New GA-ASI Gambit 6 UCAV Adds Air-To-Ground Operations for International CCA
Nov 4, 2025 23:00 HKT/SGT
|
|
|
Honda Presents World Premiere of CB1000GT Sport Tourer at EICMA 2025
Nov 4, 2025 23:55 JST
|
|
|
New CB1000GT, global debut of Honda WN7 electric motorcycle, expansion of Honda E-Clutch line-up and V3R 900 E-Compressor Prototype lead Honda's EICMA 2025 line-up
Nov 4, 2025 23:40 JST
|
|
|
Honda Motorcycle Business Product Marks and New Emblem
Nov 4, 2025 23:21 JST
|
|
|
Military Metals Announces the Commencement of Resource Confirmation Drilling at the Flagship Trojarova Antimony Gold Project, European Union
Nov 4, 2025 20:39 HKT/SGT
|
|
|
From Hong Kong Airport to Hengqin: Chimelong Ferry Sets Sail for a Worry-Free Journey 
Nov 4, 2025 16:00 HKT/SGT
|
|
|
BlackBerry and Universiti Kebangsaan Malaysia Announce Strategic Partnership to Advance Malaysia's Future Cyber-Defenders and Embedded Software Talent
Nov 4, 2025 10:00 HKT/SGT
|
|
|
Developers bring home the gold from the 15th PropertyGuru Asia Property Awards (Singapore)
Nov 4, 2025 09:30 HKT/SGT
|
|
|
The Future of Autonomous Fighters Is Coming To Rome
Nov 4, 2025 07:00 HKT/SGT
|
|
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S
Nov 3, 2025 23:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
